BHRT Study Shows 35.5% Lower Incidence of Breast Cancer in Women Treated with Subcutaneous Testosterone

BioTE founder Gary Donovitz, MD, FACOG, and Mandy Cotten, DNP, APRN, FNP-C have some exciting findings in the peer-reviewed “European Journal of Breast Health.” The 9-year testosterone therapy and breast cancer incidence study suggests that women who take testosterone in the form of hormone pellets as part of bioidentical hormone replacement therapy (BHRT), had a 35.5% lower incidence of invasive breast cancer.

This is the largest study done on testosterone pellet therapy, and the second to suggest these positive outcomes with regards to invasive breast cancer prevention. Read the full report from BioTE here.

If you’re interested in finding out more about this research study on testosterone therapy and breast cancer incidence, or want to learn how you can improve your breast health or hormone balance schedule your consultation with Dr. Kaufman today.